|Venture Round, 11/2013 ||$7.37M|
|Debt, 3/2010 ||$453k|
|Debt, 2/2012 ||$526k|
Ritter Pharmaceuticals, Inc. is committed to the discovery, development and commercialization of innovative treatments for gastrointestinal diseases. Ritter’s first target compound, RG28, has the potential to become the first FDA approved drug for the treatment of lactose intolerance, a condition that effects 80 million Americans and 4.3 billion worldwide. RG28 works by stimulating the colonic growth and colonizing lactose fermenting bacteria in the colon, which reduces lactose derived gas production, and thereby mitigates the symptoms of lactose intolerance. The drug is a 35 day treatment and only periodic maintenance treatments are needed thereafter.